As Novartis launches its self-administered multiple sclerosis drug Kesimpta, rival Roche has been looking for a convenience boost with its earlier-to-market blockbuster Ocrevus—and it just snagged a U ...
ZURICH (Reuters) - Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an ...
Roche’s Ocrevus had been growing comfortably as the top choice for new multiple sclerosis patients without major concern over competition until Novartis launched an in-class rival, Kesimpta. Now, ...
Ocrevus (ocrelizumab) and Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) are prescription medicines for multiple sclerosis (MS). Both contain the medicine ...
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton kinase (BTK) inhibitor fenebrutinib, along with data ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III OCARINA II trial evaluating Ocrevus® (ocrelizumab) ...
The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A study evaluated 182 Black and Hispanic individuals ...
Ocrevus is an intravenous (IV) infusion given every 6 months to manage certain types of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Some more common side effects are respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results